Mexican Latino patients with localized prostate cancer had significantly shorter 5-year (97% vs 99%) and 10-year (89% vs 96%) overall survival rates compared to non-Mexican Latinos.
Do prostate cancer outcomes differ among distinct Latino subpopulations compared to Non-Hispanic White patients undergoing radical prostatectomy?
Significant disparities exist in prostate cancer outcomes among Latino subpopulations, with Mexican patients experiencing worse overall and biochemical recurrence-free survival compared to other Latino groups.
Absolute Event Rate: 0% vs 0%
Objectives: Prostate cancer is the most frequently diagnosed cancer among men, with Latino patients experiencing higher cancer-specific mortality compared to non-Hispanic populations. We evaluated prostate cancer outcomes across distinct Latino subpopulations. Methods: We retrospectively reviewed a single tertiary comprehensive cancer center database of patients with localized prostate cancer treated with radical prostatectomy from 2003 through 2020. Latino patients were subcategorized as Mexican, South/Central American (SCA), or Caribbean (Puerto Rico and Cuba). Non-Hispanic White (NHW) patients served as the reference group. Results: Overall, 7084 patients were included, of which 78% (n = 5518) were NHW and 10% (n = 679) were Latinos. Compared to NHW, Latino patients were younger at the time of surgery (median 62 vs. 64 years) and had higher median BMI (median 28.8 vs. 27.5 kg/m2), median baseline PSA (6.2 vs. 5.5 ng/mL), and D’Amico intermediate- (44% vs. 42%) and high-risk disease rates (16% vs. 13%) (all p T2 was associated with worse OS. Conclusions: We identified significant differences in prostate cancer outcomes for different Latino subpopulations, underscoring the importance of population disaggregation in this ethnic group.
Jaime-Casas et al. (Mon,) reported a other. Mexican Latino patients with localized prostate cancer had significantly shorter 5-year (97% vs 99%) and 10-year (89% vs 96%) overall survival rates compared to non-Mexican Latinos.